


Economic analysis of surgery and biological therapy for CRSwNP


Patient population



ICUR
Incremental cost-utility ratio


QALY
Quality-adjusted life years

Short-term (2 years)



- Similar SNOT-22 improvement (~-31 points both groups)


Costs




ESS had similar benefit with lower cost

Long-term (10 years)

QALYs



Costs



ICUR ~€39,500/QALY
Higher benefit but higher cost

- ESS is the most cost-effective strategy
- Biologics are not cost-effective at current prices

• Cost-effectiveness may be reached only with substantial price reductions (~40%)